What Is the Stage 3C1 Cervical Cancer Survival Rate?

Five-year overall survival for stage IIIC1 cervical cancer is roughly 71%, though that single number hides enormous variation depending on tumor size, how many lymph nodes are involved, and whether cancer has spread into surrounding tissue. Some patients within this stage have outcomes closer to early-stage disease, while others face much steeper odds. Understanding what drives that spread is more useful than memorizing a single percentage.

What Stage IIIC1 Means

Under the staging system introduced by the International Federation of Gynecology and Obstetrics (FIGO) in 2018, stage IIIC1 identifies cervical cancer that has spread to pelvic lymph nodes, regardless of how large the primary tumor is or how far it extends locally. The “C1” specifically refers to pelvic nodes; if para-aortic lymph nodes are involved, the designation becomes IIIC2. A patient with a small tumor confined to the cervix but with one positive pelvic lymph node and a patient with a large tumor invading the pelvic wall who also has multiple positive nodes both receive the same IIIC1 label. That lumping together is one reason the survival statistics for this stage are so broad, and it has prompted researchers to look for ways to split the group into more meaningful risk categories.

The Published Survival Numbers

A large validation study found five-year overall survival for IIIC1 patients differed dramatically based on the size and local extent of the primary tumor: about 75% when the tumor was confined to the cervix (T1), roughly 59% when it had grown into the upper vagina or surrounding tissue (T2), and around 39% when it extended to the pelvic wall or lower vagina (T3).¹ A separate study of over 400 IIIC1 patients reported a five-year overall survival of about 71%, with the caveat that patients without parametrial involvement fared substantially better than those with it: roughly 79% versus 59%.²

Three-year disease-free survival, meaning the proportion of patients alive without any evidence of cancer recurrence at three years, has been reported at about 66% to 70% in studies of IIIC1 patients treated with standard concurrent chemoradiation.³ These figures offer a reasonable starting range, but they are averages across a mixed population. Your individual situation could look better or worse depending on several identifiable factors.

Why the Range Is So Wide

Researchers have identified two factors within stage IIIC1 that most strongly separate patients with favorable outcomes from those with poor ones: tumor size and the number of involved lymph nodes. In a study of 325 IIIC1 patients, those with tumors smaller than 4 centimeters had a three-year disease-free survival of about 85%, compared with roughly 58% for those with tumors 4 centimeters or larger. Similarly, patients with just one positive pelvic lymph node had a three-year disease-free survival near 80%, while those with two or more positive nodes dropped to about 56%.⁴

Using those two factors as a simple scoring system, the same researchers divided IIIC1 patients into three risk tiers. Patients with neither risk factor (small tumor, single positive node) had a three-year disease-free survival above 92%. Those with one factor came in around 70%. Those with both risk factors fell to about 51%.⁴ That is a gap of more than 40 percentage points within the same stage designation, which is why asking “what is the IIIC1 survival rate” without specifying these details gives you a number that may not reflect your actual prognosis at all.

An analysis of nearly 9,000 patients with locally advanced cervical cancer found that IIIC1 patients with early T-stage tumors (T1 or T2) had survival outcomes comparable to some stage II patients, while IIIC1 patients with T3 tumors did considerably worse. The authors suggested that IIIC1 should be re-stratified to reflect this reality rather than treated as a single prognostic bucket.⁵

How the Lymph Nodes Were Found Matters

Stage IIIC1 can be assigned based on imaging alone (denoted IIIC1r, for “radiologic”) or based on surgical removal and microscopic examination of the nodes (IIIC1p, for “pathologic”). This distinction turns out to have real consequences for what the survival statistics mean. A retrospective study found that patients staged as IIIC by imaging alone had five-year survival rates that were not statistically different from patients with stage I or stage II disease, while patients staged as IIIC by pathologic confirmation or by both methods had significantly worse outcomes.⁶

Part of the explanation is that imaging methods for detecting lymph node spread are imperfect. A Dutch nationwide study found that PET-CT, the most sensitive of the three major imaging tools, detected pelvic node metastases about 80% of the time, while MRI caught them about 48% and CT about 40%.⁷ Some patients classified as IIIC1r on the basis of a suspicious-looking lymph node on a scan may not actually have cancer in that node, inflating their apparent survival relative to the truly node-positive group. At the same time, some patients classified as earlier-stage disease may have microscopic nodal spread that imaging missed.

Whether para-aortic surgical staging (removing and examining higher lymph nodes to check for more distant spread) improves outcomes for IIIC1 patients is debated. A recent study found no significant survival benefit from surgical para-aortic staging compared with imaging alone in IIIC1 patients, challenging the assumption that more aggressive staging leads to better treatment tailoring.⁸

Standard Treatment and Expected Outcomes

The backbone of treatment for most IIIC1 patients is concurrent chemoradiation: external beam radiation therapy to the pelvis combined with weekly cisplatin-based chemotherapy, followed by brachytherapy, which delivers a concentrated radiation dose directly to the cervix. Brachytherapy is not optional window dressing on top of external radiation. Studies have shown that modern image-guided brachytherapy has significantly improved both local disease control and overall survival compared to older brachytherapy techniques, while also reducing serious long-term side effects.⁹

Completing the full course of radiation, including brachytherapy, within about eight weeks matters for outcomes. Research on women with locally advanced cervical cancer in rural settings found that delays in completing treatment, often driven by distance to specialized centers, limited brachytherapy access, or late referrals, were associated with worse survival trends, especially in higher-stage disease.¹⁰ If you are being treated at a facility that does not offer brachytherapy, getting a referral to one that does is one of the most important steps you can take.

Immunotherapy Is Changing the Standard

The most significant treatment advance for locally advanced cervical cancer in recent years is the addition of the immune checkpoint inhibitor pembrolizumab to standard chemoradiation. The KEYNOTE-A18 trial tested this combination in patients with high-risk locally advanced cervical cancer, and the results were strong enough to establish it as a new standard of care for this population. In the final analysis, at a median follow-up of about 42 months, adding pembrolizumab reduced the risk of death by roughly 27%, with four-year overall survival rates of about 75% in the pembrolizumab group versus 70% in the standard treatment group.¹¹

A five percentage point improvement in four-year survival may sound modest, but it translates to a meaningful number of people alive who would not have been. Pembrolizumab also significantly improved progression-free survival. The benefit was most pronounced in patients whose tumors expressed the PD-L1 biomarker at higher levels, which is worth discussing with your oncologist if immunotherapy is being considered. Approval of this regimen means that published survival statistics from studies conducted before immunotherapy was available likely underestimate what can be achieved with current treatment.

Where Recurrence Tends to Happen

Understanding recurrence patterns helps explain both why survival plateaus where it does and what surveillance strategies make sense after treatment. In a study of stage IIIC patients treated with definitive radiation, distant metastasis was the dominant failure pattern, accounting for about 80% of all recurrences. The most common site of distant spread was the lung, followed by distant lymph nodes, bone, and liver.¹² Locoregional recurrence, meaning cancer returning in the pelvis or cervix, occurred in a smaller fraction of patients and sometimes overlapped with distant spread.

The dominance of distant metastasis as the failure mode underscores why local treatment, even when technically successful at eliminating the primary tumor and involved nodes, does not always translate to cure. Microscopic cancer cells that have already escaped the pelvis before or during treatment are what drive most recurrences. This is the rationale behind adding systemic therapies like immunotherapy: they can target cells that have traveled beyond the reach of radiation. For patients who do develop recurrent or metastatic disease after initial treatment, the combination of chemotherapy with pembrolizumab has shown meaningful survival benefits, with median overall survival of about 26 months compared to roughly 17 months with chemotherapy alone in a large trial.¹³

Other Factors That Shift Individual Prognosis

Beyond tumor size, node count, and T-stage, several other variables influence how a specific IIIC1 patient is likely to do.

Hemoglobin levels before starting treatment have a measurable effect. Anemia is common in cervical cancer patients, and a study found that pre-treatment hemoglobin levels below about 9 g/dL were a significant negative predictor of progression-free survival, local control, and overall survival.¹⁴ Oxygen-poor blood makes tumor cells less sensitive to radiation, which is one reason oncologists often recommend blood transfusions or iron supplementation before or during treatment to keep hemoglobin at adequate levels. If your hemoglobin is low at diagnosis, ask your team about correcting it before radiation begins.

Age also plays a role. Older women, especially those over 70, show significantly decreased survival even when stage and tumor type are accounted for, with one large analysis reporting a hazard ratio of nearly three compared to younger patients. Part of this is biological, but part is treatment-related: older women are significantly more likely to receive less aggressive treatment regimens or, in some cases, no treatment at all.¹⁵ Fit older patients who receive full chemoradiation can do better than the age-stratified statistics suggest, so age alone should not automatically lead to treatment de-escalation.

Treatment duration, as mentioned earlier, is a modifiable factor. Completing the entire course of radiation within the recommended timeframe requires coordination between external beam and brachytherapy teams, and patients treated at high-volume centers with in-house brachytherapy capability tend to have shorter treatment times and better outcomes.

HPV Type and Multiple Infections

Nearly all cervical cancers are caused by human papillomavirus, but not all HPV types behave identically in terms of treatment response. A study of patients treated with radiation or chemoradiation found that HPV-58 and HPV-31 were associated with better prognosis, while HPV-33 predicted worse outcomes. HPV-16, the most common type overall, was linked to poorer treatment response in that particular analysis.¹⁶ The authors cautioned that these findings need confirmation in larger studies, and HPV genotype is not yet routinely used to guide treatment decisions for invasive cervical cancer.

Separately, having multiple HPV types detected in the same tumor has been associated with worse overall survival. A study examining invasive cervical cancer found that multiple HPV infection was a negative prognostic factor, while the specific presence of the most common subtypes (HPV-16 and HPV-18) alone did not significantly influence prognosis compared to less common types.¹⁷ HPV genotyping is standard at diagnosis, but its use as a treatment-guiding biomarker is still in the research phase. It is one of several areas where future advances could further refine the currently broad survival estimates for stage IIIC1.

Prophylactic Radiation to Higher Lymph Nodes

One active question in the treatment of IIIC1 disease is whether radiation fields should be extended upward to cover the para-aortic lymph nodes even when imaging shows no disease there. The reasoning is preventive: if cancer has already reached pelvic lymph nodes, it may have seeded the next station up the chain. An ongoing randomized trial is testing whether prophylactic para-aortic irradiation can reduce the rate of para-aortic recurrence from about 10% to 2% or less compared to standard pelvic-only radiation.¹⁸ Until results are available, the decision to extend the radiation field is typically made on a case-by-case basis, weighing the possible benefit against the increased side effects of treating a larger area, including greater fatigue, more gastrointestinal symptoms, and suppression of bone marrow in the spine.

This is a question worth raising with your radiation oncologist, particularly if your tumor has features that suggest a higher risk of upward spread, such as multiple positive pelvic nodes or involvement of common iliac nodes near the boundary of the standard pelvic field. Imaging of the para-aortic region, ideally with PET-CT, can help inform the decision, though even PET-CT has limited sensitivity for detecting small nodal deposits in this area.